secwatch.observer — SEC 8-K summary
======================================

Issuer:     Foghorn Therapeutics Inc. (FHTX)
CIK:        0001822462
Form:       8-K
Filed at:   2023-08-31T23:59:59+00:00
Accession:  0001628280-23-031053
Event type: other_material
Sentiment:  positive
Materiality: 0.55
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Foghorn doses first patient in Phase 1 combo study of FHD-286 for AML
---------------------------------------------------------------------

- FHD-286 in combination with decitabine or cytarabine for relapsed/refractory AML; first patient dosed.
- Data from the Phase 1 combo study expected in second half of 2024.
- Prior monotherapy study showed blast reductions and ANC recovery across genomic backgrounds.
- Preclinical models with decitabine/cytarabine improved survival vs. single-agent controls.
- Study uses 3+3 dose escalation to assess safety, tolerability, and efficacy.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1822462/000162828023031053/0001628280-23-031053-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1822462/000162828023031053/fhtx-20230831.htm
  HTML page:      https://secwatch.observer/filing/0001628280-23-031053

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer